Resources

Le cancer du col de l'utérus est le deuxième cancer le plus répandu chez les femmes en Éthiopie, avec plus de 8 000 nouveaux cas estimés en 2022. Afin de contribuer à prévenir de nouveaux cas, l'Éthiopie a introduit le vaccin contre le papillomavirus humain (HPV) en 2018. Conformément à la recommandation de l'Organisation mondiale de la santé (OMS), fondée sur des données démontrant une efficacité et une durée de protection comparables entre un schéma vaccinal à dose unique et un schéma à doses multiples, le pays est passé à un schéma à dose unique en 2024 et a mené une campagne de vaccination multi-âges (CMA) ciblant les filles âgées de 9 à 14 ans. Cette note résume les conclusions d'une étude menée par PATH en collaboration avec le ministère fédéral de la Santé sur le coût et le contexte opérationnel de l'administration du vaccin contre le HPV pendant la campagne CMA.

This brief outlines the current state of health research and development (R&D) financing in Africa and underscores the importance of sustained, country-led investment amid declining global funding. Following a temporary surge during the COVID-19 pandemic, global health R&D financing has contracted significantly. In this context, the analysis frames domestic investment and governance of health R&D as contributors to health security and sovereignty, enabling countries to set national and regional priorities. Where predictable, country-led funding is absent, R&D pathways become fragmented, slowing product development and delaying patient access to lifesaving innovations.Against this backdrop, the brief highlights the need for more coordinated and resilient approaches to financing health R&D in Africa. Drawing on discussions co-hosted by PATH and Impact Global Health, it points to strong evidence that investment in health R&D generates substantial societal and economic returns, strengthens pandemic preparedness, and supports the development of local manufacturing capacity. The recommended actions collectively aim at building sustainable, Africa-led health R&D ecosystems.

Cervical cancer is the second most common cancer among women in Ethiopia, with more than 8,000 new cases estimated in 2022. To help prevent future cases, Ethiopia introduced human papillomavirus (HPV) vaccine in 2018. Following the World Health Organization (WHO) recommendation, based on evidence of comparable efficacy and duration of protection of a single-dose HPV vaccine regimen as multiple doses, the country transitioned to a single‑dose regimen in 2024 and carried out a multi‑age cohort (MAC) campaign targeting girls aged 9 to 14 years. This brief summarizes findings from a study conducted by PATH in collaboration with the Federal Ministry of Health on the cost and operational context of HPV vaccine delivery during the MAC campaign.

Medical oxygen is a critical component of a well-functioning health system, yet only 30 percent of patients in low- and middle-income countries (LMICs) who need oxygen receive it. Key access barriers that drive this coverage gap include (1) supply and delivery challenges, such as limited production capacity, costly installation and maintenance requirements, and inadequate procurement and supply systems; (2) affordability, such as high cost of products and lack of local manufacturers; and (3) demand and adoption barriers, such as limited sustainable funding and limited guidelines.This fact sheet offers an overview of the INNOVATE project, which aims to address critical barriers to oxygen access. PATH, through a consortium of partners, will catalyze promising oxygen production and piping technologies, along with innovative operation and maintenance business models, to expand equitable access. By strengthening production and delivery capacity in health facilities and improving efficiency across the oxygen value chain, INNOVATE aims to accelerate the adoption of more cost-effective and sustainable solutions.

Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory tract infections in young children. Two preventive interventions for RSV—a maternal vaccine and long-acting monoclonal antibodies (mAbs) delivered to infants—are recommended by the World Health Organization. When countries consider introducing new vaccines, immunization program cost and affordability are key questions.To address some of these questions, the University Medical Centre Utrecht and PATH conducted studies as part of a multi-country collaboration called the RSV GOLD III-Health Economics Study to evaluate the economic burden of RSV disease (or cost of illness) and the impact and cost-effectiveness of RSV prevention (e.g., via maternal immunization or long-acting monoclonal antibodies) in Gavi, the Vaccine Alliance-eligible countries. The estimates will help inform policy decisions in low- and middle-income countries where maternal immunization-preventable diseases often hit hardest.Find here links to the peer-reviewed journal articles and select fact sheets summarizing the research. [Note: Some publications and fact sheets are forthcoming.]